About this episode
The episode discusses the significance of ApoB as a cardiovascular marker and its connection to pharmaceutical interests.
The conversation delves into the rediscovery of ApoB as a significant cardiovascular marker and its suspiciously aligned timing with pharmaceutical profit motives. It explores the comparison between ApoB and LDLC, the rise of statins, the emergence of PCSK9 inhibitors, the controversy around ApoB, the context of metabolic dysfunction, and the pharmaceutical vs. metabolic approach to ApoB. It concludes with the distinction between treating a number and treating a disease. Takeaways ApoB has become a significant cardiovascular marker The timing of ApoB's rediscovery is suspiciously aligned with pharmaceutical profit motives Chapters 00:00 Treating a Number vs. Treating a Disease
People in this episode
Host: Coach Stephen BSc Hons
Topics covered
- ApoB
- cardiovascular health
- pharmaceutical motives
- metabolic dysfunction
- statins
- PCSK9 inhibitors
- treating disease
Keywords
- ApoB
- cardiovascular marker
- pharmaceutical profit
- LDLC
- statins
- PCSK9 inhibitors
- metabolic dysfunction
Mentioned in this episode
Organizations: pharmaceutical, PCSK9 inhibitors, statins
Books & works: ApoB, LDLC
More episodes of the carnivore experience
- Dairy Myths Destroyed: Build Strong Bones Naturally · June 11, 2026 · 9 min
- Don't Fall For The Latest Cancer Claims · June 9, 2026 · 10 min
- Why Vegans Get Human Teeth Wrong · June 7, 2026 · 12 min
- Sugar and Rice Diet · June 5, 2026 · 10 min
- Never Happened Before · June 3, 2026 · 12 min
- GLP1: Side Effects · May 30, 2026 · 21 min
Explore listener stats, chart rankings, contacts and more on the the carnivore experience podcast page.